DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Information source: Novartis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acromegaly

Intervention: Octreotide acetate and cabergoline/Octrotide and Somavert (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Novartis Pharmaceuticals

Official(s) and/or principal investigator(s):
Novartis Pharmaceuticals, Study Director, Affiliation: Novartis Pharmeceuticals

Summary

This study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy

Clinical Details

Official title: A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Biochemical control (% of patients) as measured by GH- and IGF-1-values (baseline, EOS)

Secondary outcome:

Effect of tumor size

Biochemical control (mean, normalization) as measured by GH- and/or IGF-1-values

Control clinical of symptoms of acromegaly

Quality of Life assessment

Safety and tolerability as assessed by frequency of AEs

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion criteria:

- Male and female patients (> 18 years) with prior surgery of micro- or macroadenoma of

the pituitary.

- At least 6 months chronic treatment with 30mg octreotide (long acting release).

- Partial responsiveness, which is defined as follows: at any one point within the 6

months monotherapy with 30mg/month octreotide (long acting release) the patient must have experienced a decrease in GH and IGF-1 of at least 25% as compared to pre-monotherapy values (= baseline). Note: For efficacy analysis GH- and IGF-1-values measured in the central laboratory at visit 1 (=study baseline) will be used.

- Lack of suppression of GH nadir to < 1. 0 µg/L, after oral administration of 75 g of

glucose (OGTT) and IGF-I levels at least 10% above the normal value ± 2 SD (adjusted for age and gender; Brabant 2003) must be proven within 4 weeks prior to visit 1. However, if acromegaly symptoms are inadequately controlled as defined in the acromegaly comorbidities and symptom evaluation (as judged by the investigator), an abnormal GH or IGF-1-value as defined above is sufficient.

- Patient's written informed consent.

Exclusion criteria:

- Requires surgery for recent significant deterioration in visual fields or other

neurological signs, which are related to the pituitary tumor mass.

- Radiotherapy planned or radiotherapy for acromegaly within the last 2 years.

- Symptomatic cholelithiasis that is clinically relevant.

- Receiving treatment with dopamine agonists within the last 6 months or prior

treatment with GH-receptor-antagonists.

- Patients with renal insufficiency, Raynaud-Syndrome or gastrointestinal ulcer/

bleeding cannot be included in the study or psychose in anamnesis. Other protocol-defined inclusion/exclusion criteria may apply

Locations and Contacts

Novartis Investigative Site, Aachen, Germany

Novartis Investigative Site, Berlin, Germany

Novartis Investigative Site, Bochum, Germany

Novartis Investigative Site, Erlangen, Germany

Novartis Investigative Site, Essen, Germany

Novartis Investigative Site, Greifswald, Germany

Novartis Investigative Site, Heidelberg, Germany

Novartis Investigative Site, Koln, Germany

Novartis Investigative Site, Leipzig, Germany

Novartis Investigative Site, Marburg, Germany

Novartis Investigative Site, Muenchen, Germany

Novartis Investigative Site, Oldenburg, Germany

Novartis Investigative Site, Regensburg, Germany

Novartis Investigative Site, Tubingen, Germany

Novartis Investigative Site, Ulm, Germany

Novartis Investigative Site, Wurzburg, Germany

Additional Information

Starting date: March 2006
Last updated: September 22, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017